Filing Flows › Alnylam Pharmaceuticals (ALNY) › Q4 2024
Alnylam Pharmaceuticals (ALNY) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Feb 13, 2025
Alnylam Pharmaceuticals (ALNY) reported revenue of $593M for the fourth quarter 2024 (Q4 2024), +35% from a year earlier and +18% from the quarter before. Operating margin was -17.7%, net loss $83.8M (14.1% of revenue).
Alnylam Pharmaceuticals, Q4 2024: revenue $593M (+35% year over year), operating margin -17.7%, net loss $83.8M, operating cash flow −$94.7M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $593M | +18% | +35% |
| Operating profit | −$105M | — | — |
| Net earnings | −$83.8M | — | — |
| Operating cash flow | −$94.7M | — | — |
What changed
Revenue was $593.2M in Q4 2024, up 35% year over year and up 18% from the previous quarter. AMVUTTRA was the largest line at 48% of revenue.
Operating costs exceeded revenue by $105.2M, an operating margin of -17.7%. Total costs grew 26% against revenue growth of 35%. The fastest-growing cost line was SG&A (+49%). The quarter ended with a net loss of $83.8M, narrower than the previous quarter's $111.6M loss. Net interest and other expense of $88.8M was the main reason.
Operating cash flow was −$94.7M. Non-cash charges added back $14.2M of depreciation and amortization and $91.6M of share-based compensation. Working capital and other items used $116.7M. Capital expenditures of $9.1M exceeded it, leaving free cash flow of −$103.8M.
Questions
What was Alnylam Pharmaceuticals' revenue in the fourth quarter 2024?
Alnylam Pharmaceuticals (ALNY) reported revenue of $593M for the fourth quarter 2024 (Q4 2024), +35% from a year earlier and +18% from the quarter before.
Was Alnylam Pharmaceuticals profitable in the fourth quarter 2024?
Operating loss was $105M (-17.7% of revenue) and net loss $83.8M.